AstraZeneca spending £120m on Macclesfield manufacturing revamp
This article was originally published in Scrip
AstraZeneca is investing £120m ($190m) in a new facility at its global manufacturing site in Macclesfield, UK, to continue production of injectable prostate and breast cancer drug Zoladex.
You may also be interested in...
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.
Health care funding in the first half of 2020 reached $10.4bn, according to a mid-year report from Silicon Valley Bank, nearly matching 2019’s full-year record. As well as the COVID-19 pandemic though, other global events, such as the US election, could become distractions in the second half of the year.